Redeye: Lipigon Q4 2024 - Rights issue funds 2025
Redeye comments on Lipigons third quarter report, including positive phase I results for Leaderna, clinical data from Marea and the rights issue.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/